Aussie Court Battle Reveals Progen Offered Pay For Avexa Merger Votes
This article was originally published in PharmAsia News
Progen Pharmaceuticals of Australia apparently offered to pay shareholders for their votes in support of a merger with Avexa, according to information in a federal court case. At issue are conflicting schedules for shareholder meetings to decide on the Progen-Avexa merger. Progen scheduled a March 11 meeting of its shareholders to vote on the proposal, while Cytopia, an Avexa competitor, is in court seeking to delay the meeting until March 27, after it has had a chance to present its own resolution to oust Progen's board. According to court documents, Progen had offered to pay a broker a fee for all proxies that supported the merger. (Click here for more
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.